companies

Oncocidia

Founded 2014
Employees 3+
Primary contact
Anglo House
Bell Lane
HP6 6FA Amersham
United Kingdom
Links
http://www.oncocidia.com/
Diseases & Conditions
Sections
The company is developing a targeted radiopharmaceutical cancer treatment called Oncocidia. This innovative treatment involves extending the already successful use of Iodine-131 in treating thyroid cancer to treat solid cancers (primary and metastatic) elsewhere in the body. Iodine-131 is used to label the necrosis avid agent hypericin. Hypericin targets necrosis in a tumor and carries the therapeutic agent Iodine-131 to the tumor, where it is able to kill any remaining tumor cells by localized, short-range (2-3mm) beta irradiation. Oncocidia is administered in micro-dose quantities, minimizing chemotoxicities.
Founded 2014
Employees 3+
Primary contact
Anglo House
Bell Lane
HP6 6FA Amersham
United Kingdom
Links
http://www.oncocidia.com/
Diseases & Conditions
Sections

Funding 💰

Select investors NetScientific, Cetromed

Key people 🧑‍🤝‍🧑

Highlights ⭐

  • Years in the making: Oncocidia is the result of more than 15 years research conducted by the team of Professor Yicheng Ni, Head of the Theragnostic Laboratory at KU Leuven University, Belgium.
  • Based on well-understood principles: A necrotic mass is created in the tumor and a radioactive dose locates the necrosis in the tumor and irradiates what remains of it. This approach is intended to improve the treatability of most solid tumors, both primary and metastatic, including some which can be very difficult to treat.
  • Science-backed treatment: Much pre-clinical scientific work has been carried out on the Oncocidia therapy, resulting in numerous publications.
Last update: June 2, 2023